Approaches to Remyelination Therapies in Multiple Sclerosis

Lindsey Wooliscroft, Elizabeth Silbermann, Michelle Cameron, Dennis Bourdette

Research output: Contribution to journalReview article

Abstract

Purpose of review: While there are a growing number of therapies targeting relapse prevention in multiple sclerosis (MS), there are no approved therapies promoting remyelination. Understanding endogenous myelin formation, remyelination strategies, pre-clinical models, and clinical outcomes is essential to the interpretation of current and future clinical trials of remyelinating agents. Recent findings: Several recent clinical trials of remyelination therapies, including opicinumab, clemastine, and GSK239512, showed negative or modest results. These results could highlight challenges translating pre-clinical studies into subjects with MS and current strategies to measure remyelination. Summary: Current approaches to remyelination include (1) blocking inhibitors of remyelination, (2) improving the clearance of myelin debris, (3) increasing the number of oligodendrocyte precursor cells (OPCs), and (4) stimulating OPC differentiation. To date, no therapies have led to robust remyelination. Future efforts to promote remyelination will likely require a combination of these mechanistic strategies.

Original languageEnglish (US)
Article number34
JournalCurrent Treatment Options in Neurology
Volume21
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Multiple Sclerosis
Oligodendroglia
Myelin Sheath
Clemastine
Clinical Trials
Therapeutics
Secondary Prevention
Cell Differentiation

Keywords

  • Clemastine
  • GSK239512
  • Multiple sclerosis
  • Oligodendrocyte precursor cell
  • Opicinumab
  • Remyelination

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Approaches to Remyelination Therapies in Multiple Sclerosis. / Wooliscroft, Lindsey; Silbermann, Elizabeth; Cameron, Michelle; Bourdette, Dennis.

In: Current Treatment Options in Neurology, Vol. 21, No. 7, 34, 01.07.2019.

Research output: Contribution to journalReview article

@article{3c52faef0aff448cbf3deb3716d8e85f,
title = "Approaches to Remyelination Therapies in Multiple Sclerosis",
abstract = "Purpose of review: While there are a growing number of therapies targeting relapse prevention in multiple sclerosis (MS), there are no approved therapies promoting remyelination. Understanding endogenous myelin formation, remyelination strategies, pre-clinical models, and clinical outcomes is essential to the interpretation of current and future clinical trials of remyelinating agents. Recent findings: Several recent clinical trials of remyelination therapies, including opicinumab, clemastine, and GSK239512, showed negative or modest results. These results could highlight challenges translating pre-clinical studies into subjects with MS and current strategies to measure remyelination. Summary: Current approaches to remyelination include (1) blocking inhibitors of remyelination, (2) improving the clearance of myelin debris, (3) increasing the number of oligodendrocyte precursor cells (OPCs), and (4) stimulating OPC differentiation. To date, no therapies have led to robust remyelination. Future efforts to promote remyelination will likely require a combination of these mechanistic strategies.",
keywords = "Clemastine, GSK239512, Multiple sclerosis, Oligodendrocyte precursor cell, Opicinumab, Remyelination",
author = "Lindsey Wooliscroft and Elizabeth Silbermann and Michelle Cameron and Dennis Bourdette",
year = "2019",
month = "7",
day = "1",
doi = "10.1007/s11940-019-0574-1",
language = "English (US)",
volume = "21",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "7",

}

TY - JOUR

T1 - Approaches to Remyelination Therapies in Multiple Sclerosis

AU - Wooliscroft, Lindsey

AU - Silbermann, Elizabeth

AU - Cameron, Michelle

AU - Bourdette, Dennis

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Purpose of review: While there are a growing number of therapies targeting relapse prevention in multiple sclerosis (MS), there are no approved therapies promoting remyelination. Understanding endogenous myelin formation, remyelination strategies, pre-clinical models, and clinical outcomes is essential to the interpretation of current and future clinical trials of remyelinating agents. Recent findings: Several recent clinical trials of remyelination therapies, including opicinumab, clemastine, and GSK239512, showed negative or modest results. These results could highlight challenges translating pre-clinical studies into subjects with MS and current strategies to measure remyelination. Summary: Current approaches to remyelination include (1) blocking inhibitors of remyelination, (2) improving the clearance of myelin debris, (3) increasing the number of oligodendrocyte precursor cells (OPCs), and (4) stimulating OPC differentiation. To date, no therapies have led to robust remyelination. Future efforts to promote remyelination will likely require a combination of these mechanistic strategies.

AB - Purpose of review: While there are a growing number of therapies targeting relapse prevention in multiple sclerosis (MS), there are no approved therapies promoting remyelination. Understanding endogenous myelin formation, remyelination strategies, pre-clinical models, and clinical outcomes is essential to the interpretation of current and future clinical trials of remyelinating agents. Recent findings: Several recent clinical trials of remyelination therapies, including opicinumab, clemastine, and GSK239512, showed negative or modest results. These results could highlight challenges translating pre-clinical studies into subjects with MS and current strategies to measure remyelination. Summary: Current approaches to remyelination include (1) blocking inhibitors of remyelination, (2) improving the clearance of myelin debris, (3) increasing the number of oligodendrocyte precursor cells (OPCs), and (4) stimulating OPC differentiation. To date, no therapies have led to robust remyelination. Future efforts to promote remyelination will likely require a combination of these mechanistic strategies.

KW - Clemastine

KW - GSK239512

KW - Multiple sclerosis

KW - Oligodendrocyte precursor cell

KW - Opicinumab

KW - Remyelination

UR - http://www.scopus.com/inward/record.url?scp=85068065911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068065911&partnerID=8YFLogxK

U2 - 10.1007/s11940-019-0574-1

DO - 10.1007/s11940-019-0574-1

M3 - Review article

VL - 21

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 7

M1 - 34

ER -